Trial Profile
A phase Ib/II study to investigate KTE-C19 and atezolizumab in patients with refractory, aggressive non-Hodgkin lymphoma (NHL)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2016
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Atezolizumab
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Kite Pharma
- 21 Mar 2016 New trial record
- 17 Mar 2016 This trial is expected to begin in 2016, according to a Kite Pharma media release.